AMENDMENTS TO THE CLAIMS

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-64. (Canceled)

65. (Currently amended) An *in vitro* method for ~~producing~~ generating mammalian dendritic Langerhans type cells, said method comprising:

a. culturing cells selected from the group consisting of peripheral blood monocytes and bone marrow cells from a mammalian species in a medium containing platelets obtained from the same species;

b. incubating the culture at 30°C to 40°C for a period sufficient to enable ~~formation~~ *in vitro* generation of ~~mature~~ dendritic Langerhans type cells,

c. performing a morphological analysis of the *in vitro* generated dendritic Langerhans type cells ~~to demonstrate the presence of dendritic processes in cells of the culture, wherein growing colonies of cells with typical dendritic morphology are developed~~; and

d. performing flow cytometric analysis of the *in vitro* generated dendritic Langerhans type cells ~~to demonstrate an immunophenotype of dendritic Langerhans type cells in cells of the culture by using a monoclonal antibody specific for a human cell surface marker, wherein the antibody is selected from anti-CD3, anti-HLADR, anti-CD19, anti-CD40, anti-CD1a, anti-CD1b, anti-CD80, anti-CD83 and anti-CD86~~.

66. (Previously presented) The method of claim 65 wherein the medium omits an exogenous cytokine.

67. (Previously presented) The method of claim 65 wherein the medium comprises RPMI-1640.

68. (Previously presented) The method of claim 65 wherein the cells are cultured for a period of 2 to 8 days.

69. (Previously presented) The method of claim 65 wherein the medium further comprises at least 2 percent fetal calf serum.

70. (Previously presented) The method of claim 65 wherein the mammalian species is human.

71. (Currently amended) An *in vitro* method for ~~producing~~ generating human dendritic Langerhans type cells, said method comprising:

a. culturing human peripheral blood monocytes in a medium containing human platelets;

b. incubating the culture at 30°C to 40°C for a period sufficient to enable ~~formation~~ *in vitro* generation of ~~mature~~ human dendritic Langerhans type cells,

c. performing a morphological analysis of the *in vitro* generated dendritic Langerhans type cells ~~to demonstrate the presence of dendritic processes in cells of the culture, wherein growing colonies of cells with typical dendritic morphology are developed~~; and

d. performing flow cytometric analysis of the *in vitro* generated dendritic Langerhans type cells ~~to demonstrate an immunophenotype of human dendritic Langerhans type cells in cells of the culture by using a monoclonal antibody specific for a human cell surface marker, wherein the antibody is selected from anti-CD3, anti-HLADR, anti-CD19, anti-CD40, anti-CD1a, anti-CD1b, anti-CD80, anti-CD83 and anti-CD86~~.

72. (Previously presented) The method of claim 71 wherein the medium omits an exogenous cytokine.

73. (Previously presented) The method of claim 71 wherein the medium comprises RPMI-1640.

74. (Previously presented) The method of claim 71 wherein the cells are cultured for a period of 2 to 8 days.

75. (Previously presented) The method of claim 71 wherein the medium further comprises at least 2 percent fetal calf serum.

76-80. (Canceled)

81. (New) The method of claim 70, wherein the flow cytometric analysis comprises immunophenotyping the *in vitro* generated dendritic Langerhans type cells by using a monoclonal antibody specific for a human cell surface marker, wherein the antibody is selected from anti-CD3, anti-HLADR, anti-CD19, anti-CD40, anti-CD1a, anti-CD1b, anti-CD80, anti-CD83 and anti-CD86.

82. (New) The method of claim 71, wherein the flow cytometric analysis comprises using a monoclonal antibody specific for a human cell surface marker, wherein the antibody is selected from anti-CD3, anti-HLADR, anti-CD19, anti-CD40, anti-CD1a, anti-CD1b, anti-CD80, anti-CD83 and anti-CD86.